No Data
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target
Sector Update: Healthcare Stocks Decline in Afternoon Trading
MetaVia Shares Are Trading Higher After the Company Announced That All Enrolled Active Patients in Part 3 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity Have Completed Dose Titration and Are Now Receiving Their Highest...
MetaVia Says Patients on Experimental Obesity Drug Reach Highest Target Doses in Phase 1 Trial